These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

487 related items for PubMed ID: 17391170

  • 21. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes.
    Hermansen K, Davies M, Derezinski T, Martinez Ravn G, Clauson P, Home P.
    Diabetes Care; 2006 Jun; 29(6):1269-74. PubMed ID: 16732007
    [Abstract] [Full Text] [Related]

  • 22. Once-daily initiation of basal insulin as add-on to metformin: a 26-week, randomized, treat-to-target trial comparing insulin detemir with insulin glargine in patients with type 2 diabetes.
    Meneghini L, Kesavadev J, Demissie M, Nazeri A, Hollander P.
    Diabetes Obes Metab; 2013 Aug; 15(8):729-36. PubMed ID: 23421331
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. An increased dose of insulin detemir improves glycaemic control and reduces body weight of Japanese patients with diabetes.
    Fujii H, Watanabe Y, Ueki A, Ohno A, Kato M, Kondo K, Takamura H, Takesue M, Nishimura H, Matsuda D, Miyakawa T.
    Int J Clin Pract; 2010 Oct; 64(11):1512-1519. PubMed ID: 20678116
    [Abstract] [Full Text] [Related]

  • 27. Lower fasting blood glucose, glucose variability and nocturnal hypoglycaemia with glargine vs NPH basal insulin in subjects with Type 1 diabetes.
    Bolli GB, Songini M, Trovati M, Del Prato S, Ghirlanda G, Cordera R, Trevisan R, Riccardi G, Noacco C.
    Nutr Metab Cardiovasc Dis; 2009 Oct; 19(8):571-9. PubMed ID: 18676131
    [Abstract] [Full Text] [Related]

  • 28. Optimized glycaemic control achieved with add-on basal insulin therapy improves indexes of endothelial damage and regeneration in type 2 diabetic patients with macroangiopathy: a randomized crossover trial comparing detemir versus glargine.
    Fadini GP, de Kreutzenberg SV, Mariano V, Boscaro E, Bertolini F, Mancuso P, Quarna J, Marescotti M, Agostini C, Tiengo A, Avogaro A.
    Diabetes Obes Metab; 2011 Aug; 13(8):718-25. PubMed ID: 21410861
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. A one-year, randomised, multicentre trial comparing insulin glargine with NPH insulin in combination with oral agents in patients with type 2 diabetes.
    Massi Benedetti M, Humburg E, Dressler A, Ziemen M.
    Horm Metab Res; 2003 Mar; 35(3):189-96. PubMed ID: 12734781
    [Abstract] [Full Text] [Related]

  • 31. Systematic review and meta-analysis of randomized clinical trials comparing efficacy and safety outcomes of insulin glargine with NPH insulin, premixed insulin preparations or with insulin detemir in type 2 diabetes mellitus.
    Rys P, Wojciechowski P, Rogoz-Sitek A, Niesyczyński G, Lis J, Syta A, Malecki MT.
    Acta Diabetol; 2015 Aug; 52(4):649-62. PubMed ID: 25585592
    [Abstract] [Full Text] [Related]

  • 32. Glargine is superior to neutral protamine Hagedorn for improving glycated haemoglobin and fasting blood glucose levels during intensive insulin therapy.
    Fulcher GR, Gilbert RE, Yue DK.
    Intern Med J; 2005 Sep; 35(9):536-42. PubMed ID: 16105155
    [Abstract] [Full Text] [Related]

  • 33. Insulin detemir used in basal-bolus therapy in people with type 1 diabetes is associated with a lower risk of nocturnal hypoglycaemia and less weight gain over 12 months in comparison to NPH insulin.
    De Leeuw I, Vague P, Selam JL, Skeie S, Lang H, Draeger E, Elte JW.
    Diabetes Obes Metab; 2005 Jan; 7(1):73-82. PubMed ID: 15642078
    [Abstract] [Full Text] [Related]

  • 34. Insulin glargine provides greater improvements in glycaemic control vs. intensifying lifestyle management for people with type 2 diabetes treated with OADs and 7-8% A1c levels. The TULIP study.
    Blicklé JF, Hancu N, Piletic M, Profozic V, Shestakova M, Dain MP, Jacqueminet S, Grimaldi A.
    Diabetes Obes Metab; 2009 Apr; 11(4):379-86. PubMed ID: 19087105
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Patient-level meta-analysis of efficacy and hypoglycaemia in people with type 2 diabetes initiating insulin glargine 100U/mL or neutral protamine Hagedorn insulin analysed according to concomitant oral antidiabetes therapy.
    Owens DR, Traylor L, Mullins P, Landgraf W.
    Diabetes Res Clin Pract; 2017 Feb; 124():57-65. PubMed ID: 28092788
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 25.